Cytokinetics, Incorporated (Nasdaq:CYTK) announced that its Annual Meeting of Stockholders will be held on Wednesday, May 21, 2014 at 3:00 PM Pacific Time at the Embassy Suites Hotel, located at 250 Gateway Boulevard in South San Francisco, CA. Robert I. Blum, President and Chief Executive Officer, is scheduled to present an overview of Cytokinetics` performance. Cytokinetics, Inc. (NASDAQ:CYTK) net profit margin is -78.80% and weekly performance is -0.45%. On last trading day company shares ended up $4.40. Analysts mean target price for the company is $10.00. Cytokinetics, Inc. (NASDAQ:CYTK) distance from 50-day simple moving average (SMA50) is -44.91%.
ZIOPHARM Oncology Inc (NASDAQ:ZIOP) saw a large decline in short interest in April. As of April 30th, there was short interest totalling 18,661,854 shares, a decline of 9.9% from the April 15th total of 20,716,430 shares, Stock Ratings Network reports. Approximately 31.5% of the company’s stock are sold short. Based on an average daily volume of 1,068,926 shares, the short-interest ratio is presently 17.5 days. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) shares fell -5.39% in last trading session and ended the day on $3.07. Its return on assets is -102.80%. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) quarterly performance is -26.20%.
Equities researchers at Wedbush decreased their target price on shares of Infinity Pharmaceuticals Inc (NASDAQ:INFI) from $10.00 to $9.00 in a research report issued on Friday, Analyst Ratings Network reports. Wedbush’s price target would suggest a potential downside of 8.63% from the company’s current price. Infinity Pharmaceuticals Inc. (NASDAQ:INFI) shares moved down -6.07% in last trading session and was closed at $9.20, while trading in range of $8.76 – $9.89. Infinity Pharmaceuticals Inc. (NASDAQ:INFI) year to date (YTD) performance is -33.38%.
Intrexon Corp (NYSE:XON) a leader in synthetic biology, announced the appointment of Christopher Basta as Vice President of Investor Relations, effective immediately. Mr. Basta will report directly to Chairman and Chief Executive Officer Randal J. Kirk. Mr. Basta brings more than 18 years of financial experience to Intrexon. Most recently, he was a consultant for DSP Group directing its investor relations initiatives. Prior to his consulting work, Mr. Basta spent the majority of his Wall Street career at Royal Bank of Canada, where over nine years he helped establish its Middle Markets division and subsequently transitioned to assist in the growth of its Institutional Equity Sales division. Intrexon Corp (NYSE:XON) ended the last trading day at $16.71. Company weekly volatility is calculated as 8.30% and price to cash ratio as 9.30. Intrexon Corp (NYSE:XON) showed a positive weekly performance of 7.81%.
AMSC said that the Overseas Shipholding Group Inc. (OTCMKTS:OSGIQ) continues to service its financial obligations to AMSC on time. The latest confirmation hearing to exit Chapter 11 is presently scheduled for 14th July this year. Overseas Shipholding Group Inc. (OTCMKTS:OSGIQ) on last trading day company shares ended up $6.25.